.png)
.png)
Associate Professor of Medicine
University of Pittsburgh
Disclosure(s): receives research funding paid to his institution from Astellas and Merck: Grant/Research Support; serves as an advisory Board member for Astellas, Cidara, and Scynexis, served on the advisory board for Merck, Qpex Biopharma, and Shionogi: Advisor/Consultant; Venatorx and Needham & Associates: Advisor/Consultant
Dr. Clancy is Chief of Infectious Diseases for the VA Pittsburgh Healthcare System, and Tenured Professor of Medicine, Associate Chief of Infectious Diseases and Director of the XDR Pathogen Lab at the University of Pittsburgh. His research lab is funded by NIH and the VA to study molecular mechanisms of pathogenesis and antimicrobial resistance in Candida spp. and carbapenem resistant Enterobacteriaceae. He has published over 220 peer-reviewed papers on clinical, translational and bench research in diverse areas of infectious, in particular related to antimicrobial resistance in hospitalized and immunosuppressed hosts. He is chair of the Infectious Diseases Society of America's (IDSA) committee on treatment guidance for antibiotic resistant (AMR) Gram-negative infections, and serves on IDSA AMR, NIH/Antimicrobial Resistance Leadership Gram-negative infections, and EORTC/MSG fungal disease definitions committees. He is a member of study sections for grant reviews at NIH and the VA. He has received awards for clinical education from the Universities of Pittsburgh and Florida.